Status:
TERMINATED
Study Evaluating MST-997 in Advanced Malignant Solid Tumors
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
MST-997 is a taxane analog with the potential to treat subjects with a variety of tumor types. Preclinical data demonstrated that MST-997 inhibited tumor growth when administered intravenously (IV). T...
Eligibility Criteria
Inclusion
- Documented diagnosis of malignant solid tumor with measurable disease
- Life expectancy of at least 12 weeks
- ECOG (Eastern Cooperative Oncology Group) performance status of 0,1,or 2
Exclusion
- Recent major surgery, radiation therapy or anti-cancer treatment
- History of any other prior malignancy within last 5 years
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00277836
Last Update
December 8 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Houston, Texas, United States, 77030